文献速递细胞病理与分子病理神经与头颈病理

有限分子检测对液基细胞学甲状腺结节的诊断与预后价值:TERT启动子与BRAF V600E突变分析的作用

How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: Role of TERT promoter and BRAF V600E mutation analysis.
PubMed 文献 · Cancer Cytopathol · 2021-06-02

本研究对356例液基细胞学(LBC)处理的甲状腺细针穿刺(FNAC)样本(含174例手术随访)进行BRAF V600E和TERT启动子突变分析,并与组织病理学对比。BRAF V600E突变检出率为10.4%,TERT启动子突变检出率为1.1%。TERT突变病例均属于恶性阳性类别,组织学诊断为甲状腺乳头状癌高细胞亚型,且这些遗传改变与淋巴结转移(P = .0349)和更高疾病分期相关。结论认为BRAF V600E和TERT分析可在LBC样本上进行,TERT突变在分化良好的甲状腺癌中罕见但与更高分期相关,分析这些点突变仍有助于管理潜在更具侵袭性的甲状腺癌。

要点

  • BRAF V600E和TERT启动子突变分析可在液基细胞学甲状腺FNAC样本上进行。
  • TERT启动子突变在分化良好的甲状腺癌中罕见,但与本组病例中淋巴结转移和更高疾病分期相关。
  • 有限点突变分析(BRAF V600E和TERT)仍可能有助于识别和管理潜在更具侵袭性的甲状腺癌。

核心结论

  • BRAF V600E和TERT启动子突变分析可在液基细胞学样本上完成,且TERT突变虽在分化良好的甲状腺癌中罕见,但与本组病例中淋巴结转移和更高疾病分期相关。

研究设计与样本

  • 回顾性研究,纳入2013年1月至2014年6月共356例经液基细胞学处理的甲状腺FNAC样本,其中174例有手术随访。
  • 在液基细胞学和组织病理学标本上均进行BRAF V600E和TERT突变分析。

主要发现

  • BRAF V600E突变在所有病例中检出率为10.4%,TERT启动子突变检出率为1.1%。
  • TERT突变病例均属于恶性阳性类别,组织学诊断为甲状腺乳头状癌高细胞亚型。
  • 这些遗传改变与淋巴结转移(P = .0349)和更高疾病分期相关。

关键数值与推荐

  • 样本分类包括:意义不明确的异型性119例,滤泡性肿瘤42例,可疑恶性61例,恶性阳性34例。

临床怎么用

  • 在液基细胞学甲状腺FNAC样本中可开展BRAF V600E和TERT启动子突变分析,辅助诊断和预后评估。
  • 检测到TERT启动子突变可能提示更高疾病分期和淋巴结转移风险,有助于患者管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mutational analysis contributes to the diagnosis and prognosis of thyroid nodules analyzed with fine-needle aspiration cytology (FNAC). Although several advanced molecular tests based on multiple molecular markers are available for clinical use and have increased their impact on clinical management of patients, they are not widely available. Among them is BRAF V600E, one of the most studied mutations. Other genetic alterations, such as TERT promoter mutations, may coexist in thyroid carcinomas. Previous studies have demonstrated that this duet might be involved in the aggressiveness of thyroid cancer, although its prognostic value related to mortality remains undefined. The detection of such genetic alterations in thyroid liquid-based cytology (LBC) thus may assist with patient management. METHODS: From January 2013 to June 2014, 356 thyroid FNAC samples were processed by LBC, including 174 surgical follow-up samples. BRAF V600E and TERT mutation analyses were performed on both LBC and histopathology. RESULTS: The study included 119 samples categorized as atypia of undetermined significance, 42 categorized as follicular neoplasms, 61 categorized as suspicious for malignancy, and 34 categorized as positive for malignancy. BRAF V600E mutation was detected in 10.4% of all cases, whereas TERT promoter mutations were identified in 1.1%. TERT-mutated cases belonged to the positive for malignancy category, with a histologic diagnosis of tall cell variant of papillary thyroid carcinoma. These genetic alterations correlated with lymph node metastases (P = .0349) and higher disease stage. CONCLUSIONS: BRAF V600E and TERT analysis can be performed on LBC. TERT mutations are rarely identified in well differentiated thyroid carcinoma but are associated with higher stage. Although a larger molecular panel may offer more information, analyzing these few point mutations is still likely to be useful for managing potentially more aggressive thyroid carcinomas.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Dell'Aquila M, Fiorentino V, Martini M, et al. How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: Role of TERT promoter and BRAF V600E mutation analysis. Cancer Cytopathol. 2021. PMID: 34076961. doi:10.1002/cncy.22454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。